ArticleObesity surgery2026
Real-world Physical Activity and Sedentary Time Trends in Patients Undergoing Obesity Treatment: Insights From the All of Us Research Program.
Article in Obesity surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMetabolic and bariatric surgery (MBS) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) effectively reduce weight, but outcomes vary widely among individuals. While the effects of physical activity (PA) and sedentary time following obesity treatments are documented, objective wearable data in large, diverse populations remain limited. We aimed to evaluate how objective PA and sedentary time data differs between obesity treatment types and over time among patients treated with semaglutide, sleeve gastrectomy (SG), or Roux-en-Y gastric bypass (RYGB) using the All of Us Research Program.
methodsWe conducted a retrospective analysis of patients aged ≥ 18 years receiving semaglutide, SG, or RYGB. Demographic, clinical, and Fitbit-derived wearable data (step count, sedentary time, active zone minutes and maximum heart rate [HR]) were analyzed using mixed-effects linear models adjusted for demographics, BMI, and comorbidities.
resultsA total of 669 patients were included (581 semaglutide, 65 SG, 23 RYGB). Sedentary minutes significantly decreased across all treatment groups, with RYGB showing the greatest long-term reduction (25% at 5 years). Step counts did not show sustained improvement, with semaglutide and RYGB patients remaining below baseline; SG initially showed 21% increase at 4 years (not significant) that returned to baseline at 5 years. Activity minutes (lightly, fairly, and very active) did not significantly increase over time, and very active minutes declined in the surgical groups, though not significantly. Maximum heart rate increased significantly over time in all groups, with semaglutide showing the largest rise (6% at 5 years).
conclusionAll forms of obesity treatment significantly increase maximum heart rate after intervention, though the effect on other PA metrics is inconsistent and not sustained. Objective data captured via wearable devices have the potential to complement traditional follow-up, though prospective trials are needed to understand how they can be best utilized in the perioperative setting to affect patient activity.
Indexed as
Identifiers
41912836What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.